# A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)

> **NCT03642145** · PHASE3 · WITHDRAWN · sponsor: **PTC Therapeutics**

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Deflazacort

## Key facts

- **NCT ID:** NCT03642145
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-31
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is no longer necessary given the safety and efficacy of emflaza in this age range has already been established after review of already available data.
- **Last updated:** 2019-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642145, "A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03642145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*